Elsevier

Clinical Therapeutics

Volume 29, Issue 12, December 2007, Pages 2614-2634
Clinical Therapeutics

Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

https://doi.org/10.1016/j.clinthera.2007.12.034Get rights and content

Abstract

Background: Sitagliptin phosphate, the first dipeptidyl peptidase 4 (DPP-4) inhibitor, provides a new treatment option for patients with type 2 diabetes.

Objective: The purpose of this article is to review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, and cost of sitagliptin in adults with type 2 diabetes.

Methods: A literature search of MEDLINE (1966-May 10, 2007), Iowa Drug Information Service (1966-May 10, 2007), and International Pharmaceutical Abstracts (1970-May 10, 2007) was performed using the terms sitagliptin and MK-0431. English-language, original research and review articles were reviewed, as were citations from these articles. The 2005 and 2006 American Diabetes Association Scientific Abstracts were searched, and the US Food and Drug Administration review of the new drug application for sitagliptin and select information from the manufacturer were consulted.

Results: By inhibiting DPP-4, sitagliptin enhances postprandial levels of active glucagon-like peptide-1 (GLP-1), leading to a rise in insulin release and decrease in glucagon secretion from pancreatic α-cells. Sitagliptin is 87% orally bioavailable, undergoes minimal hepatic metabolism, and is primarily excreted unchanged (~79%) in the urine. At doses ≥100 mg QD, DPP-4 activity is inhibited by >80%, with a consequent 2-fold rise in active GLP-1 levels. The reduction in glycosylated hemoglobin (HbA1c) observed with 100 mg QD of sitagliptin in Phase III monotherapy trials ranged from ~0.5% to 0.6% (P ≤ 0.001 vs placebo). In Phase III combination trials, HbA1c was reduced by ~0.7% when added to metformin and ~0.9% with pioglitazone (P < 0.001 vs placebo). Markers of β-cell function, including proinsulin/insulin ratio and homeostasis model assessment of β-cell function, were improved with sitagliptin treatment. In studies, sitagliptin has been well tolerated; significant hypoglycemia and weight gain have not been noted.

Conclusions: When used alone or in combination with metformin or pioglitazone, sitagliptin has been associated with significant reductions in HbA1c and has been well tolerated. Before its place in therapy can be firmly established, long-term studies evaluating the safety of prolonged DPP-4 inhibition are necessary.

References (48)

  • MB Toft-Nielsen et al.

    Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

    J Clin Endocrinol Metab

    (2001)
  • AM Lambeir et al.

    Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV

    Crit Rev Clin Lab Sci

    (2003)
  • D Kim et al.

    (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

    J Med Chem

    (2005)
  • GR Lankas et al.

    Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9

    Diabetes

    (2005)
  • MG Beconi et al.

    Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs

    Drug Metab Dispos

    (2007)
  • SH Vincent et al.

    Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

    Drug Metab Dispos

    (2007)
  • GA Herman et al.

    Pharmaco-kinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

    Clin Pharmacol Ther

    (2005)
  • H Narita et al.

    Multiple dose administration of sitagliptin, a dipeptidyl peptide IV (DPP-4) inhibitor, in healthy Japanese subjects

  • GA Herman et al.

    Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes

    J Clin Endocrinol Metab

    (2006)
  • DQ Liu et al.

    Characterization of two cyclic metabolites of sitagliptin

    Drug Metab Dispos

    (2007)
  • XY Chu et al.

    Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein

    J Pharmacol Exp Ther

    (2007)
  • AJ Bergman et al.

    Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

    Diabetes Care

    (2007)
  • C Stevens et al.

    Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor

    Clin Pharmacol Ther.

    (2006)
  • A Bergman et al.

    Lack of a clinically meaningful effect on age, gender or obesity on the pharmacokinetics of the DPP-IV inhibitor MK-0431

  • Cited by (0)

    View full text